Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males

Stephen E. Goldstone, Heiko Jessen, Joel M. Palefsky, Anna R. Giuliano, Edson D. Moreira, Eftyhia Vardas, Carlos Aranda, Richard J. Hillman, Daron G. Ferris, Francois Coutlee, J. Brooke Marshall, Scott Vuocolo, Richard M. Haupt, Dalya Guris, Elizabeth Garner

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. This report examines the vaccine's efficacy against disease due to 10 additional non-vaccine HPV types, as well as efficacy regardless of HPV detection. The data presented suggest that vaccinating males against HPV 6, 11, 16 and 18 protects them against most vaccine HPV-type related anogenital disease. However, significant efficacy against disease due to non-vaccine HPV types was not seen. In addition, the data do not provide any evidence that vaccination with qHPV vaccine will increase the likelihood of disease caused by non-vaccine types in the short term.

Original languageEnglish (US)
Pages (from-to)3849-3855
Number of pages7
JournalVaccine
Volume31
Issue number37
DOIs
StatePublished - Aug 20 2013

Fingerprint

Papillomavirus Vaccines
Vaccines
vaccines
Human papillomavirus 18
lesions (animal)
Human papillomavirus 6
Human papillomavirus 16
Human papillomavirus 11
genitalia
vaccination
Vaccination

Keywords

  • HPV
  • Males
  • Men who have sex with men
  • Young

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Goldstone, S. E., Jessen, H., Palefsky, J. M., Giuliano, A. R., Moreira, E. D., Vardas, E., ... Garner, E. (2013). Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine, 31(37), 3849-3855. https://doi.org/10.1016/j.vaccine.2013.06.057

Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. / Goldstone, Stephen E.; Jessen, Heiko; Palefsky, Joel M.; Giuliano, Anna R.; Moreira, Edson D.; Vardas, Eftyhia; Aranda, Carlos; Hillman, Richard J.; Ferris, Daron G.; Coutlee, Francois; Marshall, J. Brooke; Vuocolo, Scott; Haupt, Richard M.; Guris, Dalya; Garner, Elizabeth.

In: Vaccine, Vol. 31, No. 37, 20.08.2013, p. 3849-3855.

Research output: Contribution to journalArticle

Goldstone, SE, Jessen, H, Palefsky, JM, Giuliano, AR, Moreira, ED, Vardas, E, Aranda, C, Hillman, RJ, Ferris, DG, Coutlee, F, Marshall, JB, Vuocolo, S, Haupt, RM, Guris, D & Garner, E 2013, 'Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males', Vaccine, vol. 31, no. 37, pp. 3849-3855. https://doi.org/10.1016/j.vaccine.2013.06.057
Goldstone SE, Jessen H, Palefsky JM, Giuliano AR, Moreira ED, Vardas E et al. Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine. 2013 Aug 20;31(37):3849-3855. https://doi.org/10.1016/j.vaccine.2013.06.057
Goldstone, Stephen E. ; Jessen, Heiko ; Palefsky, Joel M. ; Giuliano, Anna R. ; Moreira, Edson D. ; Vardas, Eftyhia ; Aranda, Carlos ; Hillman, Richard J. ; Ferris, Daron G. ; Coutlee, Francois ; Marshall, J. Brooke ; Vuocolo, Scott ; Haupt, Richard M. ; Guris, Dalya ; Garner, Elizabeth. / Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. In: Vaccine. 2013 ; Vol. 31, No. 37. pp. 3849-3855.
@article{843054c01f174c94a53f40ba80fb4a6d,
title = "Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males",
abstract = "A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. This report examines the vaccine's efficacy against disease due to 10 additional non-vaccine HPV types, as well as efficacy regardless of HPV detection. The data presented suggest that vaccinating males against HPV 6, 11, 16 and 18 protects them against most vaccine HPV-type related anogenital disease. However, significant efficacy against disease due to non-vaccine HPV types was not seen. In addition, the data do not provide any evidence that vaccination with qHPV vaccine will increase the likelihood of disease caused by non-vaccine types in the short term.",
keywords = "HPV, Males, Men who have sex with men, Young",
author = "Goldstone, {Stephen E.} and Heiko Jessen and Palefsky, {Joel M.} and Giuliano, {Anna R.} and Moreira, {Edson D.} and Eftyhia Vardas and Carlos Aranda and Hillman, {Richard J.} and Ferris, {Daron G.} and Francois Coutlee and Marshall, {J. Brooke} and Scott Vuocolo and Haupt, {Richard M.} and Dalya Guris and Elizabeth Garner",
year = "2013",
month = "8",
day = "20",
doi = "10.1016/j.vaccine.2013.06.057",
language = "English (US)",
volume = "31",
pages = "3849--3855",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "37",

}

TY - JOUR

T1 - Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males

AU - Goldstone, Stephen E.

AU - Jessen, Heiko

AU - Palefsky, Joel M.

AU - Giuliano, Anna R.

AU - Moreira, Edson D.

AU - Vardas, Eftyhia

AU - Aranda, Carlos

AU - Hillman, Richard J.

AU - Ferris, Daron G.

AU - Coutlee, Francois

AU - Marshall, J. Brooke

AU - Vuocolo, Scott

AU - Haupt, Richard M.

AU - Guris, Dalya

AU - Garner, Elizabeth

PY - 2013/8/20

Y1 - 2013/8/20

N2 - A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. This report examines the vaccine's efficacy against disease due to 10 additional non-vaccine HPV types, as well as efficacy regardless of HPV detection. The data presented suggest that vaccinating males against HPV 6, 11, 16 and 18 protects them against most vaccine HPV-type related anogenital disease. However, significant efficacy against disease due to non-vaccine HPV types was not seen. In addition, the data do not provide any evidence that vaccination with qHPV vaccine will increase the likelihood of disease caused by non-vaccine types in the short term.

AB - A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. This report examines the vaccine's efficacy against disease due to 10 additional non-vaccine HPV types, as well as efficacy regardless of HPV detection. The data presented suggest that vaccinating males against HPV 6, 11, 16 and 18 protects them against most vaccine HPV-type related anogenital disease. However, significant efficacy against disease due to non-vaccine HPV types was not seen. In addition, the data do not provide any evidence that vaccination with qHPV vaccine will increase the likelihood of disease caused by non-vaccine types in the short term.

KW - HPV

KW - Males

KW - Men who have sex with men

KW - Young

UR - http://www.scopus.com/inward/record.url?scp=84881544326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881544326&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.06.057

DO - 10.1016/j.vaccine.2013.06.057

M3 - Article

C2 - 23831322

AN - SCOPUS:84881544326

VL - 31

SP - 3849

EP - 3855

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 37

ER -